Herpes zoster in immunocompromised patients: Incidence, timing, and risk factors Peter K. Wung, MD, Janet T. Holbrook, PhD, MPH, Gary S. Hoffman, MD, Andrea K. Tibbs, BS, Ulrich Specks, MD, Y.-I. Min, PhD, Peter A. Merkel, MD, MPH, Robert Spiera, MD, John C. Davis, MD, MPH, E. William St. Clair, MD, Joseph McCune, MD, Steven R. Ytterberg, MD, Nancy B. Allen, MD, John H. Stone, MD, MPH The American Journal of Medicine Volume 118, Issue 12, Pages 1416.e9-1416.e18 (December 2005) DOI: 10.1016/j.amjmed.2005.06.012 Copyright © 2005 Elsevier Inc. Terms and Conditions
Figure Timing of herpes zoster (HZ) in relation to randomization. Kaplan-Meier curve of herpes zoster events in the Wegener’s Granulomatosis Etanercept Trial. The first 6 months after randomization corresponded to the period of the most intensive immunosuppression for this cohort. The American Journal of Medicine 2005 118, 1416.e9-1416.e18DOI: (10.1016/j.amjmed.2005.06.012) Copyright © 2005 Elsevier Inc. Terms and Conditions